logo

For the Inventor, By the Inventor

Libertyville, IL, United States of America

Qun Li

This inventor holds 19 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Abbott Laboratories Corporation, Abbvie Inc., The Trustees of Boston College. Active years: 1992-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qun Li. Retrieved from https://idiyas.com/inventor/qun-li-nmjjaa09

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 89.5

Average Co-Inventor Count = 5.4

ph-index = 7

Forward Citations = 391(Granted Patents)


Location History:

  • Gurnee, IL (US) (1992 - 1998)
  • Lbertyville, IL (US) (2011)
  • Libertyville, IL (US) (1997 - 2014)

Company Filing History:

goldMedal17 out of 4,189 
 
Abbott Laboratories Corporation
 patents
silverMedal1 out of 827 
 
Abbvie Inc.
 patents
bronzeMedal1 out of 117 
 
The Trustees of Boston College
 patents

Years Active: 1992-2014

Loading Chart...
Areas of Expertise:
ACC Inhibitors
Farnesyltransferase Inhibitors
Urea Kinase Inhibitors
Cell Proliferation Inhibitors
Kinase Inhibitors
Oxazoline Antiproliferative Agents
Imidazole Antiproliferative Agents
Chiral Compounds
Quinolizinone Compounds
Fredericamycin Derivatives
Chiral Quinolone Intermediates
4H-4-Oxo-Quinolizine
19 patents (USPTO):Explore Patents
1. 8748627 - Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome (2014-06-10),
2. 7928243 - Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome (2011-04-19),
3. 7323570 - Farnesyltransferase inhibitors (2008-01-29),
4. 7211595 - Farnesyltransferase inhibitors (2007-05-01),
5. 7056925 - Urea kinase inhibitors (2006-06-06),
6. 6924304 - Cell proliferation inhibitors (2005-08-02),
7. 6831175 - Kinase inhibitors (2004-12-14),
8. 6521658 - Cell proliferation inhibitors (2003-02-18),
9. 6228868 - Oxazoline antiproliferative agents (2001-05-08),
10. 6201001 - Imidazole antiproliferative agents (2001-03-13),
11. 5837868 - Process for preparation of chiral 3-amino-pyrrolidine and analogous (1998-11-17),
12. 5726182 - Quinolizinone type compounds (1998-03-10),
13. 5703244 - Process for preparation of chiral 3-amino-pyrrolidine and analogous (1997-12-30),
14. 5693813 - Process for preparation of 4H-4-oxo-quinolizine-3-carboxylic acid (1997-12-02),
15. 5618813 - Benzo[5.6]pyrano[2.3.4-ij]quinolizine and (1997-04-08),

Title: **Qun Li: Innovator in Metabolic Disease Solutions**

Introduction

Qun Li, based in Libertyville, IL, is an accomplished inventor with a remarkable portfolio of 19 patents. His work primarily focuses on innovations in the treatment and prevention of metabolic diseases, including obesity and diabetes.

Latest Patents

Among his latest contributions to science are his patents related to acetyl-CoA carboxylase (ACC) inhibitors. One of his significant inventions pertains to compounds that inhibit ACC, which can be utilized for preventing or treating metabolic syndrome, type II diabetes, obesity, atherosclerosis, and various cardiovascular diseases in humans. These innovations not only offer a potential pathway for new therapies but also significantly advance the understanding of metabolic conditions.

Career Highlights

Qun Li has established a solid career with notable companies such as Abbott Laboratories Corporation and AbbVie Inc. His role in these organizations has allowed him to lead various research initiatives that have resulted in significant advancements in pharmaceutical sciences.

Collaborations

Throughout his career, Qun Li has collaborated with other distinguished researchers, including Hing L Sham and Daniel T Chu. These partnerships have been instrumental in fostering innovation and facilitating the development of groundbreaking therapeutic solutions.

Conclusion

In summary, Qun Li exemplifies the spirit of innovation in the field of metabolic diseases. His extensive patent portfolio underscores his commitment to improving health outcomes through scientific advancements. As he continues to push the boundaries of research, his contributions will undoubtedly pave the way for new therapeutic approaches in managing complex metabolic disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…